Atherosclerosis Society Issues Statement on Use of PCSK9 Inhibitors, Recommending for Patients with FH, Secondary Prevention in High-Risk Patients

Atsushi Nohara The Japan Atherosclerosis Society (JAS) issued a statement on the proper use of PCSK9 inhibitors on March 2. These drugs are covered by health insurance for the primary prevention of coronary artery diseases (CAD) other than familial hypercholesterolemia...read more